Wire Stories

Genexine Abstract on GX-188E and GX-I7 Triple Combination Therapy in HNSCC Is Released at 2023 ASCO Annual Meeting

Triple combination using Genexine’s DNA vaccine GX-188E, its long-acting Interleukin-7 GX-I7 and Keytruda showed a major pathological response rate of…

3 years ago

OrBit Markets Achieves SOC 2 Type II Attestation

SINGAPORE--(BUSINESS WIRE)--OrBit Markets, the leading institutional liquidity provider in digital asset options and structured derivatives, announced today that it has…

3 years ago

Mitsubishi Electric Receives Order for Taiwan’s First STATCOM for Power Stabilization

Will help to control and stabilize diversifying power grid and support adoption of renewable energy TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO:…

3 years ago

Mitsubishi Electric and Coherent Enter into A Collaboration to Scale Manufacturing of SiC Power Electronics on A 200 mm Technology Platform

TOKYO & PITTSBURGH--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO:6503) and Coherent Corp. (NYSE: COHR), a global leader in materials, networking, and lasers,…

3 years ago

Transforming Fukushima into “Region of Recovery”: Fukushima Prefecture Releases Video of “Fukushima Now,” 12 Years after Great East Japan Earthquake

Transforming Fukushima into "Region of Recovery": Fukushima Prefecture Releases Video of "Fukushima Now," 12 Years after Great East Japan Earthquake…

3 years ago

3HOUSE.io Launches Upgraded Platform with New Trending Topics Feed and Portfolio Tracking Tools

SINGAPORE--(BUSINESS WIRE)--3HOUSE.io, the comprehensive platform for Web3 investors, has launched a series of upgrades to its platform, including a new…

3 years ago

SSR Mining Announces Voting Results From 2023 Annual Meeting of Shareholders

DENVER--(BUSINESS WIRE)--SSR Mining Inc. (NASDAQ/TSX: SSRM, ASX: SSR) ("SSR Mining" or the “Company") announces that each of the nine nominees…

3 years ago

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Highlights from early- and late-stage pipeline include -- combination data for cornerstone therapies BRUKINSA and tislelizumab -- early results for…

3 years ago

Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA

DESTINY-PanTumor02 late-breaking interim data and DESTINY-CRC02 primary results further support potential of ENHERTU across multiple HER2 expressing cancers TROPION-Lung02 updated…

3 years ago

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

− Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 30, 2023 − NDA Includes Results From…

3 years ago